Activity Overview
This CME/CMLE-accredited, case-based microlearning activity is designed
to help pathologists and laboratory professionals increase the knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum.
Every few days, participants will be emailed or sent several questions through the Qstream app. Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to prompt the participant to make an appropriate diagnosis/recommendation.
This case-based microlearning activity includes the following topics:
Best practices in IHC interpretation across the HER2 spectrum in patients with breast cancer
Clinical practice guidelines for IHC and ISH testing of HER2 in patients with breast cancer
The science and emerging evidence around HER2-low breast cancer
HER2 classification, tracking, and reporting considerations
Emerging treatment options for patients with HER2-low breast cancer
The critical importance of communication within the multidisciplinary cancer care team in the diagnosis and management of patients with breast cancer
The activity offers 1.0 CME/CMLE credit.
Target Audience
This CME/CMLE-accredited, case-based microlearning activity is designed
to help pathologists and laboratory professionals increase the knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum.
Activity Agenda
- 12 case-based microlearning questions followed by detailed explanations
- Questions are delivered 2 at a time via email or the QStream App
Learning Objectives
Upon completion of this activity, you should be able to:
- Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines
- Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer
- Update laboratory processes and procedures (eg, related to identification, tracking, and reporting) to prepare for the anticipated emergence of HER2-low as a diagnostic category of breast cancer
- Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer
Faculty
|
Swikrity U Baskota,MD, FCAP |
Assistant Professor of Pathology and Cell Biology at Columbia University Medical Center |
|
Poonam Vohra, M.D. |
Associate Professor, Anatomic Pathology, University of California, San Francisco |
Faculty Disclosures
Swikrity U Baskota,MD, and Poonam Vohra, M.D. have no relevant financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this online microlearning activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this online microlearning activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete all questions in the microlearning activity.
Commercial Support
Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.